Illumina Inc $ 334.34 12.25 (3.8%)
Warning! GuruFocus has detected 3 Medium warning signs with ILMN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ILMN (Illumina Inc) from 2000 to Dec 02 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Illumina stock (ILMN) PE ratio as of Dec 02 2020 is 77.57. More Details
Illumina PE Ratio (TTM) Historical Data
View and export this data going back to 2000. Start your Free Trial
Illumina PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:DXCM NYSE:IQV NYSE:A NAS:IDXX NYSE:MTD NYSE:LH NYSE:DGX NAS:EXAS NYSE:WAT NYSE:PKI NYSE:TMO NYSE:DHR XAMS:PHIA XSWX:LONN SHSE:603259 XPAR:BIM TSE:6869 MIL:DIA XPAR:ERF NYSE:QGEN
Address 200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 17% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.